Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.69 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.69 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.60 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.59 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3064618 | 0.95 | CHRNB2 (0.67) | CHRNB2CHRNA4CYP2A6CYP2C9CYP2C19 | |
| SCHEMBL29187190 | 0.93 | CHRNB2 (0.65) | CHRNB2CHRNA4CYP2A6CYP2C9CYP2C19 | |
| SCHEMBL14085289 | 0.89 | CHRNB2 (0.69) | CHRNB2CHRNA4CYP2A6CYP2C9CYP2C19 | |
| SCHEMBL15921874 | 0.89 | CHRNB2 (0.64) | CHRNB2CHRNA4CYP2A6CYP2C9CYP2C19 | |
| SCHEMBL3044684 | 0.87 | CHRNB2 (0.70) | CHRNB2CHRNA4CYP2A6CYP2C9CYP2C19 | |
| SCHEMBL1841748 | 0.83 | CHRNB2 (0.64) | CHRNB2CHRNA4CYP2A6CYP2C9CYP2C19 | |
| SCHEMBL23014879 | 0.82 | CHRNB2 (0.56) | CHRNB2CHRNA4CYP2A6CYP2C9CYP2C19 | |
| SCHEMBL23014820 | 0.82 | CHRNB2 (0.56) | CHRNB2CHRNA4CYP2A6CYP2C9CYP2C19 | |
| SCHEMBL7052162 | 0.82 | CYP2A6 (0.68) | CHRNB2CHRNA4CYP2A6CYP2C9CYP2C19 | |
| SCHEMBL9262058 | 0.81 | CHRNB2 (0.62) | CHRNB2CHRNA4CYP2A6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993470-B2 | Catalysts for the alkyne metathesis | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2015-03-31 | — | — | US | disclosed |
| US-8993470-B2 | Catalysts for the alkyne metathesis | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2015-03-31 | — | — | US | disclosed |
| EP-2556078-B1 | CATALYSTS FOR ALKYNE METATHESIS | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2014-09-24 | — | — | EP | disclosed |
| US-20130144102-A1 | CATALYSTS FOR THE ALKYNE METATHESIS | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2013-06-06 | — | — | US | disclosed |
| US-20130144102-A1 | CATALYSTS FOR THE ALKYNE METATHESIS | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2013-06-06 | — | — | US | disclosed |
| US-8299262-B2 | Pyridylmethyl-sulfonamide compounds | BASF SE (DE) | 2012-10-30 | — | — | US | disclosed |
| US-20100249077-A1 | Pyridylmethyl-Sulfonamide Compounds | BASF SE (DE) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130144102-A1 | CATALYSTS FOR THE ALKYNE METATHESIS | MSH6, AP3M1, PMS2 | CHRNB2 3178/4885CHRNA4 4363/4885CYP2A6 796/4885 |
| US-20100249077-A1 | Pyridylmethyl-Sulfonamide Compounds | CBR3, CBR1, CBS | CHRNB2 2999/4885CHRNA4 2029/4885CYP2A6 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.